Determining the pathophysiology of pediatric arteriovenous malformation
确定小儿动静脉畸形的病理生理学
基本信息
- 批准号:10410504
- 负责人:
- 金额:$ 67.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-10 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAllelesAnimal ModelArteriesArteriovenous malformationBirthBlood VesselsBlood capillariesBostonCandidate Disease GeneCell physiologyCellsChildChildhoodClinicalCoculture TechniquesCodeCongenital arteriovenous malformationCongestive Heart FailureCre driverDefectDeformityDiseaseEndothelial CellsEngineeringEtiologyExcisionExhibitsExploratory/Developmental Grant for Diagnostic Cancer ImagingFDA approvedFunctional disorderFundingGNAQ geneGenesGenomeGenotypeGoalsGrowthHeart failureHemorrhageHeterogeneityHistologicHumanImmunodeficient MouseImplantIndividualInfectionInterventionKnowledgeLesionLibrariesMAP2K1 geneMAPK Signaling Pathway PathwayMalignant NeoplasmsMental DepressionMethodsMitogen-Activated Protein KinasesModelingMolecularMorbidity - disease rateMorphogenesisMusMutationOperative Surgical ProceduresPainPathway interactionsPatientsPediatric HospitalsPericytesPharmaceutical PreparationsPharmacologyPharmacotherapyPhenotypePopulationPre-Clinical ModelProcessProductionProteinsRAS genesRNARecurrenceSamplingSeriesSignal PathwaySmooth Muscle MyocytesSomatic MutationSpecificitySpecimenStructureTechnologyTestingTherapeutic EmbolizationTimeTissue EngineeringTissuesUlcerVascular DiseasesVeinsVirusXenograft procedurecapillary bedcausal variantcell behaviorcell typecellular transductiondeep sequencingdesigndrug efficacyexomeexperimental studygain of functiongain of function mutationgenome sequencingimprovedin vitro testingin vivoinhibitormalformationmutantpreventprospectivepsychologicradiological imagingself esteemtargeted treatmenttissue repairtranscriptome sequencingtreatment strategyvasculogenesiswhole genome
项目摘要
The goal of this project is to understand the mechanisms by which arteriovenous malformation (AVM)
forms and progresses. This will inform us about the fundamental process of vascular morphogenesis
and, importantly, identify specific genes/pathways for which targeted therapies can be developed to
improve the lives of patients affected by AVM and other vascular diseases. AVM is present at birth
and undergoes significant progression over time. The lesion enlarges, bleeds, ulcerates, and causes
pain and deformity. Vital structures can be threatened and congestive heart failure may occur.
Currently, there is no cure for AVM and drug treatment does not exist.
We recently found that most human AVMs contain somatic mutations in MAP2K1, and that this
mutation is exclusive to the endothelial cell. We now aim to: (1) identify other somatic mutations in
human AVMs, (2) determine how MAP2K1 mutations affect endothelial cell function, and (3) develop
animal models of AVM to further study its pathophysiology as well as to test pharmacotherapy. We
will perform molecular inversion probe, RNA, whole-exome, and whole genome sequencing on AVM
tissues and isolated endothelial cells to find additional mutations in human AVMs. Mutant endothelial
cells containing the MAP2K1 mutation will be studied to determine how the mutation affects signaling
pathways, protein production, and the ability of the cells to interact with pericytes to form blood
vessels. An animal model of AVM will be developed by inserting mutant MAP2K1 endothelial cells
into immunodeficient mice, as we have successfully done with other types of vascular anomalies.
FDA-approved inhibitors of MAP2K1 will be tested in vitro and in vivo to understand the
pathophysiology of how the mutation affects cell behavior and to determine the efficacy of the drugs.
These experiments will be high impact when we succeed in identifying the pathophysiology
responsible for AVM formation and enlargement. For the first time we would be able to pursue a
targeted approach for treating this lesion. For example, pathway specific topical, intralesional, and/or
systemic pharmacologic agents could be developed to prevent AVM progression or recurrence.
Discoveries into the pathophysiology of AVM also will help us to understand the mechanisms that
underlie other pediatric vascular lesions, and will improve our ability to manipulate vascular growth in
a broad range of diseases.
这个项目的目的是了解动静脉畸形(AVM)的机制。
项目成果
期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Vascular Malformations: Current Progress Toward Drug Therapy.
- DOI:10.1097/scs.0000000000007310
- 发表时间:2021-05-01
- 期刊:
- 影响因子:0
- 作者:Greene AK;Sudduth CL
- 通讯作者:Sudduth CL
Arteriovenous malformation Map2k1 mutation affects vasculogenesis.
- DOI:10.1038/s41598-023-35301-6
- 发表时间:2023-07-08
- 期刊:
- 影响因子:4.6
- 作者:
- 通讯作者:
Arteriovenous malformation phenotype resembling congenital hemangioma contains KRAS mutations.
- DOI:10.1111/cge.13833
- 发表时间:2020-12
- 期刊:
- 影响因子:3.5
- 作者:Sudduth CL;McGuire AM;Smits PJ;Konczyk DJ;Al-Ibraheemi A;Fishman SJ;Greene AK
- 通讯作者:Greene AK
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Arin K. Greene其他文献
Somatic Arteriovenous Malformation <em>MAP2K1</em> Mutation Causes Cartilage Overgrowth by a Cell Non-Autonomous Mechanism
- DOI:
10.1016/j.jamcollsurg.2019.08.505 - 发表时间:
2019-10-01 - 期刊:
- 影响因子:
- 作者:
Jeremy A. Goss;Patrick J. Smits;Arin K. Greene - 通讯作者:
Arin K. Greene
Effect of calvarial burring on resorption of onlay cranial bone graft: An experimental study
- DOI:
10.1016/j.jamcollsurg.2010.06.216 - 发表时间:
2010-09-01 - 期刊:
- 影响因子:
- 作者:
Aladdin H. Hassanein;James E. Clune;John B. Mulliken;Praveen R. Arany;Gary F. Rogers;Ann M. Kulungowski;Arin K. Greene - 通讯作者:
Arin K. Greene
Surgical Treatment of Gynecomastia Improves Quality of Life in Adolescents: A Longitudinal Cohort Study
- DOI:
10.1016/j.jamcollsurg.2017.07.375 - 发表时间:
2017-10-01 - 期刊:
- 影响因子:
- 作者:
Joseph M. Firriolo;Carolyn M. Pike;Laura C. Nuzzi;Arin K. Greene;Brian I. Labow - 通讯作者:
Brian I. Labow
Lower Extremity Lymphatic Function Predicted by BMI: A Lymphoscintigraphic Study of Obesity and Lipedema
- DOI:
10.1016/j.jamcollsurg.2020.07.340 - 发表时间:
2020-10-01 - 期刊:
- 影响因子:
- 作者:
Arin K. Greene;Christopher L. Sudduth - 通讯作者:
Christopher L. Sudduth
Engraftment of human MSCs as perivascular cells of bioengineered microvessels enhances mesenchymal tissue formation
- DOI:
10.1016/j.carpath.2013.01.066 - 发表时间:
2013-05-01 - 期刊:
- 影响因子:
- 作者:
Ruei-Zeng Lin;Arin K. Greene;Juan M. Melero-Martin - 通讯作者:
Juan M. Melero-Martin
Arin K. Greene的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Arin K. Greene', 18)}}的其他基金
Determining the pathophysiology of pediatric arteriovenous malformation
确定小儿动静脉畸形的病理生理学
- 批准号:
10163060 - 财政年份:2018
- 资助金额:
$ 67.42万 - 项目类别:
Determining the Mechanism for Infantile Hemangioma: Follicle-Stimulating Hormone
确定婴儿血管瘤的机制:卵泡刺激激素
- 批准号:
8751873 - 财政年份:2014
- 资助金额:
$ 67.42万 - 项目类别:
Determining the Mechanism for Infantile Hemangioma: Follicle-Stimulating Hormone
确定婴儿血管瘤的机制:卵泡刺激激素
- 批准号:
8909155 - 财政年份:2014
- 资助金额:
$ 67.42万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 67.42万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 67.42万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 67.42万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 67.42万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 67.42万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 67.42万 - 项目类别:
Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 67.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 67.42万 - 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 67.42万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 67.42万 - 项目类别: